Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY‐5445, vinpocetine and 1‐methyl‐3‐isobutyl‐8‐(methylamino)xanthine
Open Access
- 1 November 1989
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 98 (3) , 725-734
- https://doi.org/10.1111/j.1476-5381.1989.tb14599.x
Abstract
1 The mechanism by which M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine (MIMAX), which have been described as selective cyclic GMP phosphodiesterase (PDE) inhibitors, relax rat aorta was investigated. 2 Three cyclic nucleotide PDEs were identified in the soluble fraction of rat aorta; a Ca2+-insensitive form exhibiting substrate selectivity for cyclic GMP (cGMP PDE), a Ca2+/calmodulin-stimulated form which also preferentially hydrolyzed cyclic GMP (Ca2+ PDE), and a form demonstrating substrate selectivity for cyclic AMP (cAMP PDE). 3 M&B 22,948 and MIMAX inhibited cGMP PDE (Ki = 0.16 μm and 0.43 μm, respectively) and Ca2+ PDE (Ki = 9.9 μm and 0.55 μm, respectively), but exhibited weak activity against cAMP PDE (Ki = 249 μm and 42 μm, respectively). MY-5445 selectivity inhibited cGMP PDE (Ki = 1.3 μm) and vinpocetine selectively inhibited Ca2+ PDE (Ki = 14 μm). 4 M&B 22,948 and MIMAX induced dose-dependent increases in the accumulation of cyclic GMP, but not cyclic AMP, in rat aorta pieces. These effects were greatly reduced by endothelial denudation and by methylene blue (5 μm) which blocks the actions of endothelium-derived relaxant factor. MY-5445 and vinpocetine had no effect on rat aorta cyclic GMP or cyclic AMP accumulation. 5 All four compounds caused dose-related relaxation of 5-hydroxytryptamine (10 μm) contracted, endothelium-intact rat aorta, the effects of M&B 22,948 and MIMAX being greatly reduced by methylene blue (5 μm). Methylene blue also caused 10 fold and 100 fold rightward shifts in the dose-response curves of MY-5445 and vinpocetine, respectively. 6 The results are consistent with the smooth muscle relaxant actions of M&B 22,948 and MIMAX, but not vinpocetine and MY-5445, being mediated through a mechanism involving inhibition of cyclic GMP hydrolysis.Keywords
This publication has 19 references indexed in Scilit:
- Direct binding studies on ileal and cardiac muscarinic receptorsBritish Journal of Pharmacology, 1987
- Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aortaBiochemical Pharmacology, 1987
- Effects of isoproterenol on active force and Ca2+ · calmodulin-sensitive phosphodiesterase activity in porcine coronary arteryBiochemical Pharmacology, 1987
- Cyclic guanosine monophosphate as a mediator of vasodilation.Journal of Clinical Investigation, 1986
- Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aortaBiochemical Pharmacology, 1986
- A New Generation of Phosphodiesterase Inhibitors: Multiple Molecular Forms of Phosphodiesterase and the Potential for Drug SelectivityJournal of Medicinal Chemistry, 1985
- Selective inhibitors of three forms of cyclic nucleotide phosphodiesterasesTrends in Pharmacological Sciences, 1984
- Cyclic GMP mediates neurogenic relaxation in the bovine retractor penis muscleBritish Journal of Pharmacology, 1984
- Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscleBiochemical Pharmacology, 1984
- Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthinesJournal of Medicinal Chemistry, 1981